Veracyte, Inc. reported total revenue of $150.3 million [1] for the second quarter of 2026, marking a 15% increase year-over-year [1].
The results demonstrate the market's adoption of the company's newest diagnostic tools. Growth in this sector suggests a shift toward more precise molecular testing in clinical settings.
Testing revenue for the quarter reached $145.7 million [1]. This specific segment grew by 19% compared to the same period last year [1]. The company said this momentum was due to the launch and subsequent integration of the Prosigna and TrueMRD diagnostic tests [4].
These products are designed to provide more accurate data for patient diagnosis and monitoring. The increased testing volume has contributed to a stronger cash flow for the organization [3].
Looking ahead, Veracyte provided updated financial guidance for the remainder of 2026. The company expects total annual revenue to fall between $570 million and $582 million [2].
This guidance implies an expected year-over-year total revenue growth of 10% to 13% for the full year [2]. Testing revenue specifically is projected to grow between 14% and 16% [2].
Market analysts said the upward revision in guidance followed the earnings beat in the second quarter [4]. The company continues to advance its product launches to sustain this trajectory through the end of the year.
“Total revenue for Q2 2026 reached $150.3 million.”
The growth in testing revenue, which is outpacing total revenue growth, indicates that Veracyte's core business is becoming more dependent on high-value specialized diagnostics. By successfully launching Prosigna and TrueMRD, the company is diversifying its portfolio and reducing reliance on older product lines, positioning itself to capture a larger share of the precision medicine market.
